Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 5.02 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2026-03-31
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-12-31 was 3.55M shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-09-30 was 192.50K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2024-12-31 was -4.62M shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2020-12-31 was -3.29M shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2025 was 5.02M shares, a 1210.63% increase from fiscal 2024.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2024 was 383.33K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2020 was 234.83K shares, a 17.42% increase from fiscal 2019.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2019 was 200.00K shares, a 5.20% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 3.55M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 3.74M shares derived: sum of 2 quarters · filed 2026-03-31 | 5.02M shares 10-K · filed 2026-03-31 | ||
| 2025-09-30 | 192.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 1.48M shares 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 1.28M shares 10-Q · filed 2025-08-05 | ||||
| 2024-12-31 | -4.62M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 383.33K shares 10-K · filed 2026-03-31 | 5.00M shares 10-K · filed 2025-02-27 | ||
| 2024-09-30 | 5.00M shares 10-Q · filed 2024-11-07 | ||||
| 2020-12-31 | -3.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -2.97M shares derived: sum of 2 quarters · filed 2022-03-31 | -2.97M shares derived: sum of 3 quarters · filed 2022-03-31 | 234.83K shares 10-K · filed 2022-03-31 | 3.52M shares 10-K · filed 2021-03-19 |
| 2020-09-30 | 322.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | 322.52K shares derived: sum of 2 quarters · filed 2020-11-16 | 3.52M shares 10-Q · filed 2020-11-16 | 3.52M shares derived: sum of 4 quarters · filed 2021-03-19 | |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | 3.20M shares 10-Q · filed 2020-08-14 | 3.20M shares derived: sum of 3 quarters · filed 2021-03-19 | 3.20M shares derived: sum of 4 quarters · filed 2021-03-19 | |
| 2020-03-31 | 3.20M shares 10-Q · filed 2020-05-15 | 3.20M shares derived: sum of 2 quarters · filed 2021-03-19 | 3.20M shares derived: sum of 3 quarters · filed 2021-03-19 | ||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | 0.00 shares derived: sum of 2 quarters · filed 2021-03-19 | 200.00K shares 10-K · filed 2021-03-19 | ||
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | 200.00K shares 10-Q · filed 2019-11-14 | |||
| 2019-06-30 | 200.00K shares 10-Q · filed 2019-08-14 | ||||
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | 0.00 shares derived: sum of 2 quarters · filed 2020-03-25 | 190.11K shares 10-K · filed 2020-03-25 | ||
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | 190.11K shares 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | 190.11K shares 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |